共 46 条
Distribution of weight, stature, and growth status in children and adolescents with spinal muscular atrophy: An observational retrospective study in the United States
被引:4
|作者:
Darras, Basil T.
[1
]
Guye, Sabrina
[2
]
Hoffart, Janine
[2
]
Schneider, Sophie
[2
]
Gravestock, Isaac
[2
]
Gorni, Ksenija
[3
]
Fuerst-Recktenwald, Sabine
[2
]
Scalco, Renata S.
[4
]
Finkel, Richard S.
[5
]
De Vivo, Darryl C.
[6
,7
]
机构:
[1] Harvard Med Sch, Boston Childrens Hosp, Dept Neurol, Boston, MA 02115 USA
[2] F Hoffmann La Roche Ltd, Grenzacherstr 124, CH-4070 Basel, Switzerland
[3] F Hoffmann La Roche Ltd, PDMA, Neurosci & Rare Dis, Basel, Switzerland
[4] F Hoffmann La Roche Ltd, Pharma Dev Neurol, Basel, Switzerland
[5] St Jude Childrens Res Hosp, Ctr Expt Neurotherapeut, Memphis, TN USA
[6] Columbia Univ, Irving Med Ctr, Dept Neurol, New York, NY 10027 USA
[7] Columbia Univ, Irving Med Ctr, Dept Pediat, New York, NY 10027 USA
关键词:
body mass index;
growth status;
height;
obesity;
spinal muscular atrophy;
weight;
BODY-COMPOSITION;
MANAGEMENT;
DIAGNOSIS;
GENE;
CARE;
SMN;
D O I:
10.1002/mus.27556
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
Introduction/Aims Data regarding weight, height/length, and growth status of patients with spinal muscular atrophy (SMA) who have received only supportive care are limited. This cross-sectional study describes these measurements in patients with Type 1 and Types 2/3 SMA and compares them with reference values from typically developing children. Methods Retrospective baseline data from three sites in the Pediatric Neuromuscular Clinical Research Network (Boston, New York, Philadelphia) were used. Descriptive statistics for weight, height/length, body mass index-for-age, as well as weight-for-length and absolute and relative deviations from reference values (ie, 50th percentile from World Health Organization/Centers for Disease Control growth charts) were calculated. Furthermore, growth status was reported. Results A total of 91 genetically confirmed patients with SMA receiving optimal supportive care and without any disease-modifying treatment were stratified into Types 1 (n = 28) and 2/3 SMA (n = 63). Patients with Type 1 SMA weighed significantly less (median = -7.5%) compared with reference values and patients with Types 2/3 SMA were significantly shorter (mean = -3.0%) compared with reference values. The median weight was considerably below the 50th percentile in both groups of patients, even if they received a high standard of care and proactive feeding support. Discussion More research is needed to understand which factors influence growth longitudinally, and how to accurately capture growth in patients with SMA. Further research should investigate the best time to provide feeding support to avoid underweight, especially in patients with Type 1, and how to avoid the risk of overfeeding, especially in patients with Types 2/3 SMA.
引用
收藏
页码:84 / 90
页数:7
相关论文